Zymeworks filed its FY2025 10-K on March 2, same day it announced a $250M loan from Royalty Pharma. That's not a coincidence — it's a company staging its coming-out party as a royalty aggregation vehicle.

The thesis is simple. The evidence is strong. And you probably can't make money on it.

The Royalty Pharma Tell

Royalty Pharma reviewed 480+ deals in 2025. Closed 8. A 2% acceptance rate. They deployed $250M secured by 30% of ZYME's Ziihera (zanidatamab) royalties from Jazz and BeOne.

RPRX doesn't do charity. Their implied math: ≈$10-11B cumulative zanidatamab sales through 2042, peak annual sales $1.5-2.5B. Total repayment obligation: $481M on the $250M (1.925x), or $412.5M if ZYME pays early by 2033 (1.65x).

The deal validates the royalty stream at institutional grade. But it comes with teeth — RPRX now has effective veto power over any amendment to Jazz/BeOne agreements, any sale of Ziihera IP, and any further royalty monetization. The cost of non-dilutive capital is reduced strategic flexibility on the company's most valuable asset.

The GEA Binary

Jazz is submitting an sBLA for zanidatamab in first-line HER2+ gastroesophageal adenocarcinoma (GEA) this quarter — Q1 2026, under Real-Time Oncology Review with Breakthrough Therapy Designation. Jazz's R&D head called it "the agent of choice in first-line GEA" on the Q4 call. Not "we hope." Not "we plan to evaluate." Agent of choice.

Phase 3 HERIZON-GEA-01 delivered:

• 26.4-month median OS (longest ever reported in Phase 3 GEA)
• 35% reduction in disease progression risk vs trastuzumab
• 20.7-month duration of response vs 8.3 months control — 2.5x improvement
• 70.7% ORR

If approved: $250M milestone from Jazz. On a $1.8B market cap.

The competitive positioning is better than you'd think. Zanidatamab and Enhertu (Daiichi Sankyo's T-DXd) are sequential, not competing — zanidatamab in first-line, Enhertu in second-line. Jazz's own breast cancer trial (EmpowHER-303) treats patients post-T-DXd progression, explicitly acknowledging Enhertu as upstream. Daiichi initiated DESTINY-Gastric05 to test Enhertu in first-line, but data is years away. Zanidatamab has the 1L field to itself for now.

The Factor Decomposition

Eight independent value drivers. Here's the math:

Mid-case sum: $2.5B vs $1.8B market cap. That's +39% upside. Analyst consensus says +60% (mean target $38.54), which sits between our mid and high cases.

Enterprise value after stripping ≈$400M excess cash: $1.3B. GEA alone at 80% P(approval) is worth $1.2-1.5B. The market is pricing GEA at a discount and assigning approximately zero to everything else — BTC royalties on an already-approved drug, breast cancer Phase 3, J&J prostate Phase 3, own ADC pipeline, royalty acquisition optionality.

The Bear Signals

The CFO was fired. The 10-K said "departed." The 8-K (Item 5.02) says "terminated." Leone Patterson was fired from all positions on January 9, 2026 — three days after receiving a share award. CEO Kenneth Galbraith now holds four hats: Chair, CEO, interim CFO, and principal accounting officer. General Counsel also departed. The board-mandated "not due to disagreement" language is legally required boilerplate. Read: CEO cleaning house for the royalty model pivot.

The options market is nervous. Put/call OI ratio of 8.34 — that's 851 puts to 102 calls. ATM implied vol at 151%, which is 4x the 30-day realized vol of 39%. IV is at the 163rd percentile of its 52-week range, meaning it's literally above the prior year's maximum. Major put positions at $18 (502 contracts, cheap insurance at $0.05) and $22 (349 contracts). Smart money is hedging the binary.

Q4 earnings missed. Actual -$0.55 vs consensus -$0.32 (-70.6% miss), after three consecutive beats. The milestone-dependent revenue model is inherently lumpy — feature not bug, but the market punishes quarter-to-quarter.

Pasritamig is crowded. J&J initiated Phase 3 for their ZYME-partnered prostate cancer bispecific, but the mCRPC field is a knife fight — Janux showed 73% PSA50, Vir showed 82%, Amgen's xaluritamig is already in Phase 3. And J&J's own 10-K has zero mentions of pasritamig. When a $450B company doesn't mention your drug in their annual filing, you're not a priority.

The Cash Story

This is where the pivot gets real.

70% burn reduction in one year. Revenue up 39% to $106M (milestone-driven). Zero ATM shares sold despite having a facility. Instead, $62.5M deployed in buybacks at an average of $24.22. Management is buying back stock and securing non-dilutive capital simultaneously.

Pro-forma liquidity: $520M. No going concern language. Costs guided lower in 2026.

Why You Probably Can't Trade This

14 analysts. 100% bullish. Mean target +60%. Market cap $1.8B. 1Y return +98.5%.

This is a known story being told by every sell-side desk with a biotech practice. The GEA binary is the consensus catalyst. The royalty pivot is the consensus narrative. The options market is already pricing the event risk.

Where's the edge? Not in GEA approval probability (14 analysts model it). Not in Jazz commercial trajectory (their team knows). Not in pasritamig competitive dynamics (prostate KOLs know). Not in royalty model valuation (RPRX just did the math for you).

The one interesting angle is sector misclassification — biotech multiples transitioning to royalty company multiples as ZYME executes acquisitions with its $520M war chest. But Stifel, Leerink, and HC Wainwright all raised targets on this exact thesis within days of the RPRX announcement.

The Setup That Would Change the Math

A CRL on GEA or a material filing delay would crater this below $15. At that level, BTC royalties (already approved) + $520M cash would cover the market cap, and you'd get breast cancer Phase 3, pasritamig, own pipeline, and royalty model optionality for free. That's when the options market's put insurance becomes your entry signal.

Until then: well-understood thesis, strong fundamentals, no informational edge for anyone who doesn't have Jazz's prescriber data or an oncology KOL network.

Score the filing bullish. Score the trade neutral.